-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for ketorolac tromethotriol injections approved and issued by the State Drug Administration. Ketorolac trometriol injection is suitable for short-term treatment of moderate to severe acute pain requiring opioid level analgesia in adults (no more than 5 days). It is usually used for post-operative analgesia, and is not suitable for the treatment of mild or chronic pain.
Share
Listen to the news
Zhitong Finance App News, Huahai Pharmaceutical (600521.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for ketorolac tromethotriol injections approved and issued by the State Drug Administration. Ketorolac trometriol injection is suitable for short-term treatment of moderate to severe acute pain requiring opioid level analgesia in adults (no more than 5 days). It is usually used for post-operative analgesia, and is not suitable for the treatment of mild or chronic pain.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending